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Abstract: We report two patients with psychotic depression who were successfully treated 
with a lithium addition to ongoing paroxetine treatment. In both cases, plasma brain-derived 
neurotrophic factor (BDNF) levels increased about 2-fold after lithium augmentation to par-
oxetine, compared with paroxetine treatment alone. Plasma paroxetine levels did not change 
after lithium addition. These results suggest that the increases in plasma BDNF levels reﬂ  ect 
recovery from depressive symptoms in psychotic depression.
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Introduction
It has been well established that about half of all treatment-refractory depressed patients 
respond to the addition of lithium to their ongoing antidepressant regimen, usually 
within 1–2 weeks (Lenox and Manji 1998). Zullino and Baumann (2001) reported 
in their review that lithium augmentation in depressive patients who do not respond 
to selective serotonin reuptake inhibitors (SSRIs) including citalopram, ﬂ  uoxetine, 
paroxetine, and sertraline, may be an efﬁ  cacious and generally well-tolerated treat-
ment, with a response rate of at least 50% after a period lasting 1–2 weeks; there is as 
yet no clearer evidence for a pharmacokinetic interaction between lithium and SSRIs 
with pharmacodynamic consequences.
Recently, Karege et al (2002) reported that serum BDNF levels were signiﬁ  cantly 
decreased in antidepressant-free depressed patients, and that serum BDNF levels 
were negatively correlated with the Montgomery-Asberg Depression Rating Scale. 
Shimizu et al (2003) also demonstrated that serum BDNF was signiﬁ  cantly lower in 
an antidepressant-naïve depressed group than in either a treated or a control group, 
and that there was a signiﬁ  cant negative correlation between serum BDNF and Ham-
ilton Rating Scale for Depression (Ham-D) scores in all patients. Furthermore, they 
reported preliminary ﬁ  ndings that decreased serum BDNF levels in antidepressant-
naïve patients recovered to normal levels in association with lower Ham-D scores after 
treatment with antidepressant medication. Moreover, Lang et al (2004) demonstrated 
that decreased serum BDNF levels were observed in healthy volunteers with neuroti-
cism, a depression-related personality trait. The authors also speculated that BDNF 
levels have some inﬂ  uence on central serotonergic activity. Recently, we reported that 
plasma BDNF levels increased 4 weeks after high-frequency repetitive transcranial 
magnetic stimulation treatment in treatment-refractory depressed patients, and the 
increase was related to the improvement of the depressive symptoms (Yukimasa et al 
2006). Taken together, it is possible that serum or plasma BDNF level is one of the 
biological state markers for a depressive state.Neuropsychiatric Disease and Treatment 2007:3(5) 684
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In the present study, we report two cases of psychotic 
depression responding to lithium augmentation to an ongo-
ing paroxetine regimen. In both cases, the plasma BDNF 
level increased after the lithium addition to the paroxetine 
treatment, and were related to the patient’s recovery from 
depressive symptoms.
Measurement of plasma BDNF 
and paroxetine
All blood samples were taken at 7 am before breakfast (at 
least 12 hours after the last medication). Seven milliliters 
of venous blood was drawn with the patient in the supine 
position, after the patient had been lying at rest. The plasma 
samples were quickly separated in a centrifuge (2000 g, 
10 min, 4 °C) and stored at –80 °C until assay.
The plasma BDNF levels were measured using a BDNF 
Emax Immunoassay Kit (Promega, Madison, WI, USA) 
according to the manufacturer’s instructions. Plasma par-
oxetine was also analyzed by high-performance liquid 
chromatography (HPLC) according to the method of Gupta 
(1994). The protocol of this study was approved by the Ethics 
Committee of the University of Occupational and Environ-
mental Health. All patients gave their consent to participate 
after having been informed of the study’s purpose.
Case reports
Case 1
The patient was a 60-year-old housewife with a major depres-
sive disorder with psychotic features by DSM-IV criteria. 
She had ﬁ  rst depressive episode at the age of 45-year-old. 
She was recovered from the depressive episode treated 
with imipramine (100 mg/day). She had second depressive 
episode (insomnia, depressed mood, restlessness, agita-
tion, anxiety, fatigue) after interferon-alpha treatment for 
hepatitis C, however, she had no cognitive and neurologi-
cal impairment. Her score on the Ham-D was 32. She had 
not comorbid any other psychiatric and physical disorders. 
Within 6 weeks her depressive symptoms were successfully 
treated with paroxetine at 40 mg/day. She was maintained 
with paroxetine at 40 mg/day for 6 months and then parox-
etine was tapered off. One year later, she became depressed 
again with depressive mood, anxiety, restlessness, agitation 
and mood incongruent persecutory delusion (her score in the 
Ham-D was 28). Paroxetine was re-started and increased up 
to 40 mg/day. Her plasma BDNF level just before paroxetine 
administration was 0.8 ng/mL. Four weeks later, there was no 
evidence of improvement of her depressive symptoms, her 
Ham-D score was still 25, and her plasma levels of BDNF 
and paroxetine were 0.9 ng/mL and 110 ng/mL, respectively. 
Lithium at 400 mg/day was added to the ongoing paroxetine. 
A week after the lithium addition, her depressive symptoms 
were dramatically improved (her Ham-D score was 12), and 
the improvement continued. Mild ﬁ  nger tremor transiently 
occurred after lithium augmentation without any treatment. 
She was remitted 2 weeks after the lithium augmentation (her 
Ham-D score was 7). Her plasma levels of BDNF, paroxetine, 
and lithium at 4 weeks after lithium addition were 1.8 ng/mL, 
124 ng/mL, and 0.5 mEq/L, respectively.
Case 2
The patient was a 65-year-old housewife with a major depres-
sive disorder with psychotic features by DSM-IV criteria. She 
had no previous depressive episodes. Three months after her 
husband died of bladder cancer, she became depressed with 
depressive mood, anxiety, agitation, restlessness, hypochon-
driasis, psychomotor retardation, insomnia, fatigue, and mood-
incongruent persecutory delusion (her Ham-D score was 32). 
She had not comorbid any other psychiatric and physical dis-
orders. Paroxetine was started and increased up to 40 mg/day. 
Her plasma BDNF level just before paroxetine administration 
was 1000 pg/mL. Four weeks later, her depressive symptoms 
had not improved, her Ham-D score had worsened to 35, and 
her plasma levels of BDNF and paroxetine were 1.1 pg/mL and 
98 ng/mL, respectively. Lithium at 400 mg/day was added to 
the ongoing paroxetine treatment. Two weeks after the lithium 
addition, her depressive symptoms were gradually improved 
(her Ham-D score was 21), and the improvement continued. 
Her Ham-D scores 3 and 4 weeks after lithium addition were 
15 and 7, respectively. Any adverse effects did not occurred 
after lithium addition. Her plasma levels of BDNF, paroxetine, 
and lithium at 4 weeks after lithium addition were 2.4 ng/mL, 
108 ng/mL, and 0.4 mEq/L, respectively.
Discussion
Psychotic depression is known to be particularly resistant to 
treatment with tricyclic antidepressant drugs or SSRIs alone 
(Chan et al 1987; Matthews et al 2002); it has been reported 
that patients with psychotic depression respond better to a 
combination of antipsychotic drugs and antidepressant drugs 
than to antidepressant drugs alone (Nelson and Bowers 1978; 
Charney and Nelson 1981). Recently, we reported that com-
bination treatments of risperidone with antidepressant drugs 
or mood stabilizers were effective for psychotic depression, 
and the inﬂ  uence of risperidone on dopaminergic activity is 
associated with its efﬁ  cacy (Goto et al 2006). However, the 
combination treatments of typical or atypical antipsychotic Neuropsychiatric Disease and Treatment 2007:3(5) 685
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drugs with antidepressants drugs are sometimes accompanied 
with adverse side effects such as extrapyramidal symptoms, 
hyperprolactinemia, weight gain or hyperglycemia. Another 
strategy for psychotic depression is lithium augmentation to 
antidepressant drugs (Ebert 1997). The major ﬁ  nding in the 
present study is that plasma BDNF levels did not change after 
4 weeks after paroxetine treatment; however, they increased 
about 2-fold at 4 weeks after lithium augmentation to par-
oxetine compared with paroxetine treatment alone, related 
with the recovery from depressive symptoms in both cases. 
The average plasma BDNF level in health volunteers is 2.2 ± 
1.4 ng/mL (mean ± SD) (data not shown). Thus, the plasma 
BDNF levels of the two patients were recovered within nor-
mal levels. In the present cases, the lithium addition to parox-
etine was effective for the treatment of psychotic depression. 
There is growing evidence indicating that BDNF may have a 
crucial role in mental disorders such as depression (Durman 
et al 1997) and schizophrenia (Shoval and Weizman 2005). 
Karege et al (2002) shown that serum BDNF levels of drug-
free patients are lower than those of controls, and Shimizu
et al (2003) found that serum BDNF levels of treated 
depressed patients do not different from control levels. 
Aydemir et al (2005) have reported that serum BDNF levels 
are lower in depressed patients than those in controls, and that 
treatment with antidepressant drugs for 12 weeks increases 
serum BDNF levels to control levels. Gonul et al (2005) 
have also reported that treatment with several antidepressant 
drugs for 8 weeks signiﬁ  cantly increases serum BDNF levels 
to the same levels as those of control subjects. In addition, 
we have reported that serum BDNF levels in responders 
are signiﬁ  cantly increased 2.6- and 1.8-fold 8 weeks after 
treatment with paroxetine or milnacipran, respectively 
(Yoshimura et al 2007). On the other hand, nonresponders are 
not. These results indicate that blood BDNF levels is a state 
marker for depressive states, and antidepressant drugs with 
or without lithium increase serum BDNF levels in both non-
psychotic and psychotic depressed patients. In other words, 
blood BDNF levels might be a biological marker for the 
response to the pharmacological intervention in depressive 
state. Previously, we reported that treatment with paroxetine 
for 8 weeks, but not 4 weeks increased blood BDNF levels 
in the responders to paroxetine (Yoshimura et al 2007). In 
the present cases, lithium addition to the ongoing paroxetine 
increased the BDNF levels 4 weeks after the combination 
treatment. These results suggest that lithium augmentation 
to paroxetine might have more potent effects on the BDNF 
levels. The amount of plasma BDNF levels appear to be much 
lower than serum, because a lot of BDNF exist in platelet, 
and Karege et al (2005) reported that both serum and plasma 
levels were decreased in depressed patients compared with 
control subjects, suggesting that the alteration of serum or 
plasma BDNF is not due to the change in blood BDNF but 
rather is probably related to mechanisms of BDNF release, 
which is independent of platelet activity. Furthermore, plasma 
paroxetine concentrations did not change after the lithium 
augmentation, suggesting that pharmacokinetic interaction 
between paroxetine and lithium might not be associated with 
the mechanism for plasma BDNF increases and recovery 
from the psychotic depression by lithium augmentation to 
paroxetine. However, the possibility that paroxetine treat-
ment might have increased plasma BDNF levels very slowly 
is not completely ruled out. In addition, there is a possibility 
that other mechanisms such as enhancing serotonergic and 
noradrenergic neurons (Terao et al 1992; Terao et al 2000) 
by lithium might be associated with their improvement.
In conclusion, lithium augmentation to ongoing paroxetine 
treatment was effective for the treatment of two psychotic 
depressive patients. Although plasma BDNF levels did not 
alter with only paroxetine treatment, they increased after lith-
ium addition to paroxetine. Further study is needed to elucidate 
the mechanisms for the efﬁ  cacy of the combination treatment 
of lithium and paroxetine and the increase of plasma BDNF 
levels induced by lithium augmentation to paroxetine.
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